利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

23 条记录 (耗时 0.027 秒)

    Dosage Forms and Related Therapies
    2.
    发明申请
    Dosage Forms and Related Therapies 有权
    剂型和相关疗法

    公开(公告)号：US20150164826A1

    公开(公告)日：2015-06-18

    申请号：US14573211

    申请日：2014-12-17

    申请人： Garth James Smith Cooper ,  John Richard Baker ,  Nigel Robert Arnold Beeley

    发明人： Garth James Smith Cooper ,  John Richard Baker ,  Nigel Robert Arnold Beeley

    IPC分类号： A61K31/131 ,  A61K31/194

    CPC分类号： A61K31/132 ,  A61K9/0019 ,  A61K31/131 ,  A61K31/194 ,  A61K31/30

    摘要： This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogues, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.

    摘要翻译： 本发明部分地涉及这样的剂量和剂量制剂的新剂量，剂量制剂和给药途径，所述剂量和剂量制剂含有一种或多种铜螯合剂，例如一种或多种三胺活性剂，包括三嗪类似物， 三碘胺盐，三氮烯前药和三异胺衍生物，可用于治疗疾病，病症和病症，包括铜可能发挥作用的适应症。

    Preventing and/or treating cardiovascular disease and/or associated heart failure
    4.
    发明授权
    Preventing and/or treating cardiovascular disease and/or associated heart failure 有权
    预防和/或治疗心血管疾病和/或相关的心力衰竭

    公开(公告)号：US08034799B2

    公开(公告)日：2011-10-11

    申请号：US11221298

    申请日：2005-09-07

    申请人： Garth J. S. Cooper ,  John R. Baker

    发明人： Garth J. S. Cooper ,  John R. Baker

    IPC分类号： A61K31/33 ,  A61K31/315 ,  A61K31/195 ,  A61K31/185 ,  A61K31/07 ,  A61K33/32

    CPC分类号： A61K31/197 ,  A61K31/13 ,  A61K31/198 ,  A61K31/30 ,  A61K31/38 ,  A61K31/45 ,  A61K33/30 ,  A61K33/34 ,  A61K45/06

    摘要： Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems, (iv) plaque rupture of atheromatous lesions of major blood vessels such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the fermoral arteries and the popliteal arteries, (v) diabetes or the complications of diabetes.

    摘要翻译： 提供了用于减少铜值的方法，例如，治疗，预防或改善组织损伤，例如可能由（i）心脏病（例如心肌病或心肌炎）引起的组织损伤， 例如特发性心肌病，包括糖尿病性心肌病，酒精性心肌病，药物性心肌病，缺血性心肌病，高血压性心肌病等的代谢性心肌病，（ii）主要血管（大血管病）如动脉粥样硬化性疾病如冠状动脉， 颈动脉，脑血管动脉，肾动脉，髂动脉，股动脉和al动脉，（iii）毒性，药物诱导和代谢（包括小血管的高血压和/或糖尿病性疾病（微血管 疾病），例如视网膜小动脉，肾小球小动脉，神经紧张，心脏小动脉和相关毛细血管床 眼睛，肾脏，心脏和中枢和周围神经系统的斑块破裂，（iv）主要血管的动脉粥样硬化病变的斑块破裂，例如主动脉，冠状动脉，颈动脉，脑血管动脉，肾脏 动脉，髂动脉，股动脉和al动脉，（v）糖尿病或糖尿病并发症。

    Dosage Forms and Related Therapies
    6.
    发明申请
    Dosage Forms and Related Therapies 审中-公开

    公开(公告)号：US20200276135A1

    公开(公告)日：2020-09-03

    申请号：US16719404

    申请日：2019-12-18

    申请人： PhilEra New Zealand Limited

    发明人： Garth James Smith Cooper

    IPC分类号： A61K31/132 ,  A61K31/30 ,  A61K31/131 ,  A61K31/194 ,  A61K9/00

    摘要： This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogues, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.

    Preventing And/Or Treating Cardiovascular Disease And/Or Associated Heart Failure
    8.
    发明申请
    Preventing And/Or Treating Cardiovascular Disease And/Or Associated Heart Failure 有权
    预防和/或治疗心血管疾病和/或相关心力衰竭

    公开(公告)号：US20140113969A1

    公开(公告)日：2014-04-24

    申请号：US14029984

    申请日：2013-09-18

    申请人： PHILERA NEW ZEALAND LIMITED

    发明人： Garth J.S. Cooper ,  John R. Baker

    IPC分类号： A61K31/197

    CPC分类号： A61K31/197 ,  A61K31/13 ,  A61K31/198 ,  A61K31/30 ,  A61K31/38 ,  A61K31/45 ,  A61K33/30 ,  A61K33/34 ,  A61K45/06

    摘要： Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) drug induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems, (iv) plaque rupture of atheromatous lesions of major blood vessels such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the fermoral arteries and the popliteal arteries, (v) diabetes or the complications of diabetes.

    摘要翻译： 提供了用于减少铜值的方法，例如，治疗，预防或改善组织损伤，例如可能由（i）心脏病（例如心肌病或心肌炎）引起的组织损伤， 例如特发性心肌病，包括糖尿病性心肌病，酒精性心肌病，药物性心肌病，缺血性心肌病，高血压性心肌病等的代谢性心肌病，（ii）主要血管（大血管病）如动脉粥样硬化性疾病如冠状动脉， 颈动脉，脑血管动脉，肾动脉，髂动脉，股动脉和al动脉，（iii）药物诱导和代谢（包括小血管（微血管病）的高血压和/或糖尿病性疾病） 作为视网膜小动脉，肾小球小动脉，神经伏脉，心脏小动脉和相关毛细血管床 e眼，肾脏，心脏和中枢和周围神经系统，（iv）主要血管（如主动脉，冠状动脉，颈动脉，脑血管动脉，肾动脉）的动脉粥样硬化病变的斑块破裂， 髂动脉，股动脉和al动脉，（v）糖尿病或糖尿病并发症。

    Dosage forms and related therapies
    9.
    发明授权
    Dosage forms and related therapies 有权

    公开(公告)号：US10543178B2

    公开(公告)日：2020-01-28

    申请号：US15966433

    申请日：2018-04-30

    申请人： PhilERA New Zealand Limited

    发明人： Garth James Smith Cooper

    IPC分类号： A61K31/132 ,  A61K31/30 ,  A61K31/131 ,  A61K31/194 ,  A61K9/00

    摘要： This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogues, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.